Traj35: A Non-Functional T Cell Receptor Alpha-Joining 35 (G28720)

Target Name: TRAJ35

NCBI ID: G28720

TRAJ35

Other Name(s): T cell receptor alpha joining 35 (non-functional)

Traj35: A Non-Functional T Cell Receptor Alpha-Joining 35

T cell receptor alpha-joining 35 (TRAJ35) is a protein that is expressed in various tissues throughout the body, including the skin, lungs, and gastrointestinal tract. It plays a critical role in the immune system, specifically in T cell function. Unfortunately, despite its importance,Traj35 is also known as a non-functional T cell receptor alpha-joining 35 (TRAJ35).

The T cell receptor alpha-joining 35 (TRAJ35) is a transmembrane protein that is composed of two extracellular domains and an intracellular domain. The extracellular domains consist of a N-terminal domain that is involved in cell adhesion and interaction, a catalytic domain that is responsible for catalyzing chemical reactions, and a C-terminal domain that contains a unique juxtamolecular interaction with the intracellular domain.

The intracellular domain of Traj35 is a nucleotide-binding oligomerization domain (NBD) that is involved in the regulation of DNA binding and gene expression. It consists of a nucleotide-binding domain and a domain that contains a leucine-rich repeat (LRR) sequence. The LRR sequence plays a critical role in the formation of a nucleotide-binding oligomerization domain and is involved in the regulation of DNA binding and gene expression.

TRAJ35 is a key regulator of T cell development and function. During T cell development, Traj35 is involved in the regulation of the decision to differentiate into an T cell or a natural killer cell. It also plays a critical role in the regulation of T cell receptor (TCR) function, as well as the regulation of T cell proliferation and apoptosis.

In addition to its role in T cell development and function, Traj35 is also involved in the regulation of inflammation and autoimmune diseases. It has been shown to be involved in the regulation of inflammation in response to infection or injury, as well as in the regulation of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis.

Despite its importance in T cell development and function, Traj35 is also known as a non-functional T cell receptor alpha-joining 35 (TRAJ35). This means that it does not function as a T cell receptor, but it is still involved in the regulation of T cell development and function.

Traj35 is a potential drug target for the treatment of various diseases. For example, it has been shown to be involved in the regulation of rheumatoid arthritis (RA), a chronic autoimmune disease that affects millions of people worldwide. Traj35 has also been shown to be involved in the regulation of multiple sclerosis, another autoimmune disease that can cause significant disability and suffering.

In addition to its potential as a drug target, Traj35 may also be used as a biomarker for the diagnosis and monitoring of various diseases. For example, it can be used as a biomarker for the diagnosis of RA, as it is often expressed at higher levels in individuals with RA. It can also be used as a biomarker for the diagnosis of multiple sclerosis, as it is often expressed at higher levels in individuals with MS.

In conclusion, Traj35 is a non-functional T cell receptor alpha-joining 35 (TRAJ35) that is involved in the regulation of T cell development and function, as well as the regulation of inflammation and autoimmune diseases. Despite its importance, Traj35 is also known as a non-functional T cell receptor alpha-joining 35 (TRAJ35), which means that it does not function as a T cell receptor. However, it is

Protein Name: T Cell Receptor Alpha Joining 35 (non-functional)

The "TRAJ35 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRAJ35 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets